Hyperfine, Inc.
HYPR
FAIR PRICE VALUATION
Updated daily
Model: DCF 50% · Relative 30% · Consensus 20%
MARKET PRICE
$1.21
FAIR PRICE
$0.64
MARGIN
$0.57
P/E Ratio
N/A
Div. Yield
N/A
ROE
-97.4%
Market Cap
$93M
Small-cap
COMING SOON
Get notified when HYPR's fair price changes
Fair Price Index app is launching soon with push notifications when valuations shift for stocks you follow.
iOS and Android · Free tier available
KEY FACTS
CEO
Maria Degois-Sainz
COUNTRY
US
HEADQUARTERS
Guilford
SECTOR
Healthcare
EXCHANGE
NASDAQ
METHODOLOGY
How we calculate HYPR's fair price
Hyperfine, Inc.'s fair price of $0.64 is derived from a blended model that combines DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%). At the current market price of $1.21, HYPR trades 47.1% above its calculated fair value.
DCF MODEL · 50%
Discounted cash flow analysis based on projected free cash flows, discounted at a rate reflecting HYPR's risk profile.
RELATIVE · 30%
Comparing HYPR's valuation multiples against Healthcare peers.
ANALYST · 20%
Aggregated analyst price targets for HYPR, weighted by recency and analyst accuracy.
POWERED BY BULIOS
Get full analysis, financials, and AI insights for HYPR.
Explore on BuliosFAQ
What is the fair price of HYPR?+
Based on our blended model combining DCF analysis (50%), relative valuation against Healthcare peers (30%), and analyst consensus (20%), the fair price for Hyperfine, Inc. is $0.64. At the current market price of $1.21, HYPR trades 47.1% above its calculated fair value.
Is HYPR overvalued or undervalued?+
Hyperfine, Inc. is currently overvalued based on our valuation model. The stock trades at $1.21, which is 47.1% above the fair price of $0.64.
How often is HYPR's fair price updated?+
We update fair price calculations for HYPR daily after market close. The current fair price of $0.64 incorporates the latest market data and sector multiples.
What factors affect HYPR's fair price calculation?+
HYPR's fair price of $0.64 is derived from DCF analysis (50% weight), relative valuation against Healthcare peers (30% weight), and analyst consensus (20% weight)., ROE of -97.4%.
Is HYPR a good buy right now?+
At $1.21, HYPR trades 47.1% above our fair value estimate of $0.64. The stock is currently overvalued. ROE stands at -97.4% (average). Fair Price Index provides valuation data — always do your own research before investing.
Does HYPR pay dividends?+
HYPR does not currently pay a dividend.